Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus

A Li, F Guo, Q Pan, S Chen, J Chen, H Liu… - Frontiers in …, 2021 - frontiersin.org
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Although previous
studies have demonstrated that SLE is related to the imbalance of cells in the immune …

Comprehensive overview of COVID-19-related respiratory failure: focus on cellular interactions

F Zamani Rarani, M Zamani Rarani… - Cellular & Molecular …, 2022 - Springer
The pandemic outbreak of coronavirus disease 2019 (COVID-19) has created health
challenges in all parts of the world. Understanding the entry mechanism of this virus into …

Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study

M Abbasifard, H Khorramdelazad, A Rostamian… - Trials, 2023 - Springer
Backgrounds N-acetylcysteine (NAC) has broadly been used as an anti-oxidant agent in
various types of diseases. This study aimed to assess the effect of NAC on the systemic …

Effect of treatment regimen of the rheumatoid arthritis patients on the risk of coronavirus disease 2019 by modulating the inflammatory mediators

Z Bagheri‑Hosseinabadi, A Dehghani, MA Lotfi… - …, 2023 - Springer
Background The therapeutic profile of the patients with rheumatoid arthritis (RA) commonly
consists of immunosuppressive and anti-inflammatory compounds. Here in this research, we …

Synergistic effects of BTN3A1, SHP2, CD274, and STAT3 gene polymorphisms on the risk of systemic lupus erythematosus: a multifactorial dimensional reduction …

YY Tang, WD Xu, L Fu, XY Liu, AF Huang - Clinical Rheumatology, 2024 - Springer
Objective Systemic lupus erythematosus is a complex autoimmune disorder, and evidence
supports the significance of genetic polymorphisms in SLE genetic susceptibility. The aim of …

Regional variations in serum IL-35 levels and association with systemic lupus erythematosus: a systematic review and meta-analysis

N Leerach, K Ngaosuwan, W Mahikul - Scientific Reports, 2024 - nature.com
Abstract Interleukin (IL)-35 is an anti-inflammatory cytokine that regulates autoimmune
diseases, including systemic lupus erythematosus (SLE). However, the association between …

The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?

M Abbasifard, K Bagherzadeh… - Frontiers in …, 2024 - frontiersin.org
Clobenpropit is a histamine H3 receptor antagonist and has developed as a potential
therapeutic drug due to its ability to inhibit CXCR4, a chemokine receptor involved in …

A glance on the role of IL-35 in systemic lupus erythematosus (SLE)

D Bahadorian, TA Faraj, RK Kheder, SK Najmaldin… - Cytokine, 2024 - Elsevier
It is well known that systemic lupus erythematosus (SLE) is an auto-inflammatory disease
that is characterized by chronic and widespread inflammation. The exact pathogenesis of …

Interleukin-35 in autoimmune dermatoses: Current concepts

Y Xie, H Zhang, J Huang, Q Zhang - Open Medicine, 2022 - degruyter.com
Abstract Interleukin-35 (IL-35) is a lately observed cytokine and is part of the IL-12 cytokine
family. IL-35 includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and …

[HTML][HTML] Lymphocytes Change Their Phenotype and Function in Systemic Lupus Erythematosus and Lupus Nephritis

E Moysidou, M Christodoulou, G Lioulios… - International Journal of …, 2024 - mdpi.com
Systemic lupus erythematosus (SLE) is a complex autoimmune disease, characterized by
considerable changes in peripheral lymphocyte structure and function, that plays a critical …